

Jean-Luc Raoul

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10687876/jean-luc-raoul-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58

papers

25,382

citations

33

h-index

60

g-index

60

ext. papers

30,583

ext. citations

10.7

avg, IF

6.41

L-index

#	Paper	IF	Citations
58	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. <i>Clinical Therapeutics</i> , 2021 , 43, 1201-1212	3.5	0
57	Expected outcomes and patients selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results. <i>World Journal of Clinical Cases</i> , 2021 , 9, 4559-4572	1.6	1
56	Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/ β Catenin Pathway in Genomic Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 564506	5.3	2
55	Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. <i>Lancet Oncology</i> , 2020 , 21, 479-481	21.7	20
54	Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2019 , 6, HEP11	4	11
53	Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. <i>Liver Cancer</i> , 2019 , 8, 457-467	9.1	19
52	Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 1414-1423	2.2	2
51	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019 , 72, 28-36	14.4	163
50	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018 , 69, 182-236	13.4	3196
49	Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. <i>Surgical Oncology</i> , 2018 , 27, 619-624	2.5	2
48	Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein. <i>Journal of Hepatocellular Carcinoma</i> , 2018 , 5, 91-98	5.3	7
47	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2395-2406	59.2	1047
46	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018 , 68, 16-24	14.4	89
45	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. <i>Journal of Hepatology</i> , 2017 , 66, 1166-1172	13.4	128
44	Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. <i>Molecular and Clinical Oncology</i> , 2017 , 6, 44-48	1.6	13
43	Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. <i>EMBO Molecular Medicine</i> , 2017 , 9, 482-497	12	50
42	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1624-1636	21.7	400

41	An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1467-1476	4	18
40	An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value. <i>PLoS ONE</i> , 2017 , 12, e0177977	3.7	2
39	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 545-557	40	630
38	Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. <i>Oncotarget</i> , 2016 , 7, 45649-45655	3.3	16
37	How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2016 , 8, 1541-1546	3.4	9
36	Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. <i>Targeted Oncology</i> , 2016 , 11, 815-824	5.24	33
35	Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. <i>Journal of Gastrointestinal Cancer</i> , 2016 , 47, 15-9	1.6	7
34	Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 339-46	8.9	87
33	Intermediate-stage HCC--upfront resection can be feasible. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12,	19.4	6
32	Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 10	19.4	14
31	Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. <i>Liver Cancer</i> , 2015 , 4, 16-25	9.1	27
30	Treatment of intermediate-stage hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 525-35	19.4	315
29	High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1786-90	8.9	110
28	How to define transarterial chemoembolization failure or refractoriness: a European perspective. <i>Liver Cancer</i> , 2014 , 3, 119-24	9.1	90
27	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. <i>Hepatic Oncology</i> , 2014 , 1, 181-188	4	14
26	Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2014 , 3, 439-50	9.1	18
25	One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization. <i>World Journal of Gastroenterology</i> , 2014 , 20, 5131-4	5.6	11
24	Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2518-25	3.15	64

23	Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3517-24	2.2	568
22	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3509-16	2.2	468
21	Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 23-9	2.2	310
20	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 639-51	2.2	27
19	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. <i>Cancer</i> , 2012 , 118, 147-58	6.4	217
18	Why is pancreatic cancer difficult to treat in the elderly?. <i>Aging Health</i> , 2012 , 8, 301-307		1
17	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. <i>Journal of Hepatology</i> , 2012 , 56, 1080-1088	13.4	88
16	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012 , 57, 821-9	13.4	589
15	Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 255-63	8.9	199
14	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 173-85	4.2	51
13	FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. <i>New England Journal of Medicine</i> , 2011 , 364, 1817-25	59.2	4650
12	Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. <i>New England Journal of Medicine</i> , 2011 , 364, 501-13	59.2	1817
11	Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer. <i>Medical Oncology</i> , 2011 , 28 Suppl 1, S246-9	3.7	0
10	Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). <i>BMC Cancer</i> , 2011 , 11, 346	4.8	79
9	Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. <i>Clinical Cancer Research</i> , 2011 , 17, 1973-83	12.9	130
8	Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010 , 7, 41-9	24.2	41
7	Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen. <i>Nuclear Medicine and Biology</i> , 2010 , 37, 777-84	2.1	13
6	First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 453-61	8.8	34

5	Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 858-64	8.9	196
4	Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. <i>European Journal of Cancer</i> , 2009 , 45, 1788-97	7.5	52
3	Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. <i>World Journal of Gastroenterology</i> , 2009 , 15, 713-6	5.6	34
2	Sorafenib in advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 378-90	59.2	9089
1	Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4338-46	2.2	107